Eyeforpharma Real World Evidence Conference Round up 2018
Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)
This year has seen a turning point for Japan's pharma industry, as the government and the industry encourage a rapid move towards increased use of RWE from April 2018. Real World Data (RWD) sources provide an unprecedented opportunity for companies to find, demonstrate and communicate their real value to patients, healthcare and society. The conference included topics addressing commercial and medical needs, allowing both communities to come together for the first time encouraging collaboration across functions.
EphMRA Annual Conference 2018
Visit us on stand number 20
We are delighted to be presenting, exhibiting and sponsoring the EphMRA Annual Conference in Basel, from 26-28 June. Representing Research Partnership at the event are Senior Director Angela Duffy, Director Richard Head, and Associate Director An-hwa Lee.
Live from Singapore: Full speed ahead - Unlock the full potential of your brand tracking
You know that you need to conduct regular research to track the performance of your brand. But is your brand tracking delivering the insights your stakeholders need?
If you’re setting up a new brand tracker or you’ve already got one but you’re not sure it’s performing at its best, this webcast is for you.
Connected Patients - Adopting a patient-centric approach in emerging markets
The concept of patient centricity and putting the patient at the heart of care is being widely adopted by the healthcare industry – the general consensus being that it’s going to be critical to future success.
Combination therapies in oncology: The benefits of integrated insights
In association with Pharmaceutical Executive
Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.